Drug Topics
MARCH 11, 2024
A panel discussion at the Outcomes 2024 SYNC National Conference touched upon many important themes in community pharmacy, including the evolving role of pharmacists, emerging tech, and key challenges going forward.
Pharmacy Times
MARCH 12, 2024
This guide discusses the integration of continuous glucose monitoring (CGM) technology into clinical practice, emphasizing the role of pharmacists in selecting and optimizing CGM devices for patients.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 12, 2024
Discover why gut bacteria are considered the next frontier in medicine in this informative article. Learn about the importance of the microbiome, its impact on health, and how it relates to conditions like Clostridiales difficile.
Pharmaceutical Commerce
MARCH 14, 2024
This financial toxicity is quite prominent, but what can be done to remedy treatment costs?
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmacy Times
MARCH 12, 2024
Integrate nutrition into the health care system with a proactive approach to chronic disease management
Drug Topics
MARCH 13, 2024
Recent studies on daylight saving time’s association with increased health risks have heightened the debate on whether to observe the biannual event or switch to one universal time.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
MARCH 14, 2024
A new study suggests the antiviral drug obeldesivir may be effective in curing Ebola Sudan infections, for which there are currently no approved vaccines or treatments. Scientists at the University of Texas Medical Branch in Galveston tested the drug, made by Gilead, in primates, starting treatment 24 hours after the animals were given what should have been a lethal dose of Sudan ebolavirus by intramuscular injection.
Pharmacy Times
MARCH 14, 2024
This finding was evident in both examined groups and regardless of the patients' B-cell maturation antigen-directed therapy status.
Drug Topics
MARCH 13, 2024
Since changes in vaccine composition can sometimes lead to confusion or misinformation, effective communication is crucial to promote vaccine uptake.
PharmaVoice
MARCH 12, 2024
As colorectal deaths rise among younger people, a diagnostic could help pinpoint more patients.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
MARCH 14, 2024
WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to the drug for people on Medicare, experts told STAT. Currently, Medicare is prohibited by law from covering medications for obesity treatment alone. While companies that manufacture wildly popular anti-obesity medications and their allies haven’t been successful in lobbying Congress to change the law , the Food and Drug
Pharmacy Times
MARCH 14, 2024
At 4 months, 75% of participants achieved remission and no longer showed signs of depression symptoms in a phase 2 clinical trial.
Drug Topics
MARCH 13, 2024
Cybin’s proprietary deuterated psilocybin analog, CYB003, provided robust and sustained improvements in depression symptoms in a phase 2 study.
PharmaVoice
MARCH 13, 2024
Biotech IPOs are off to the races in 2024, and investors are betting on horses that are derisked in targeted areas.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
MARCH 12, 2024
Over the past year, I have watched many children die of measles. In the final stages, little lungs, filled with fluid and racked with inflammation, struggle for oxygen. The victims breathe faster and faster, gasping for air until, exhausted, they stop.
Pharmacy Times
MARCH 12, 2024
The cream significantly reduced abscesses and inflammatory nodules, reaffirming its efficacy as a maintenance option for HS.
Drug Topics
MARCH 15, 2024
A blood-based cell-free DNA (cfDNA) test was able to find patients at increased risk of colorectal cancer (CRC), advanced neoplasia, and advanced precancerous lesions.
PharmaVoice
MARCH 11, 2024
One rare disease survivor’s diagnosis experience highlights the need for pharma companies to better understand the patient journey.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Pharma
MARCH 15, 2024
Pfizer knew 2023 was going to be a challenging year of transition. But even the drugmaker was surprised by the plummeting demand for its COVID-19 products, missing badly on its 2023 guidance. | After a difficult year for Pfizer, in which its share price fell by 44%, CEO Albert Bourla’s compensation fell by 35% from $33 million in 2022 to $21.6 million in 2023.
Pharmacy Times
MARCH 11, 2024
Contract pharmacies should work to stay in a perpetual state of audit readiness
Drug Topics
MARCH 11, 2024
Complementary health approaches, like yoga or acupuncture, can be particularly appealing to patients seeking natural and non-invasive approaches to improve their health.
STAT
MARCH 12, 2024
DETROIT — Every morning, Rebecca Smith, nursing a surgically repaired knee, carefully walks down the hallway of her brutalist brick apartment building, takes the elevator one floor to the lobby, and negotiates the sharply angled driveway outside. There, she waits for an Uber to take her to the last place she wants to go: her methadone clinic.
The Guardian - Pharmaceutical Industry
MARCH 10, 2024
Confronted by the huge salaries on offer in the US, London boardrooms are lobbying to be allowed to make their own bosses even wealthier There was a sharp intake of breath last month when the pharmaceuticals group AstraZeneca cemented chief executive Pascal Soriot’s position as the best-paid FTSE 100 boss with a £17m pay package , up from £15.3m a year earlier.
Pharmacy Times
MARCH 11, 2024
The IVIG therapies were previously approved for 4-week room temperature storage conditions of 25º Celsius during the first 24 months of shelf life.
Drug Topics
MARCH 14, 2024
The approval, awarded to Madrigal Pharmaceuticals, was based on phase 3 data demonstrating that resmetirom achieved broad treatment effects in patients with MASH with liver fibrosis.
STAT
MARCH 11, 2024
UnitedHealth Group quietly acquired dozens of outpatient facilities in 2023, with a particular focus on surgery centers, according to a STAT review of company financial filings. Those acquisitions — nearly all of which the company never announced — build on the network of some 90,000 physicians UnitedHealth Group has amassed in recent years.
Fierce Healthcare
MARCH 12, 2024
ORLANDO — It's almost impossible to have a conversation at HIMSS24 without the topic of artificial intelligence or generative AI coming up. | How will the conversations about AI in healthcare change by next year's HIMSS conference? Hackensack Meridian CEO Robert Garrett predicts that pilot projects underway now will roll out into practice.
Pharmacy Times
MARCH 13, 2024
Aspirin, known as acetylsalicylic acid, has been marketed in ways that have de-emphasized potential risks to children.
Drug Topics
MARCH 14, 2024
With growing concerns around opioid use disorder, interventional pain management for patients with cancer can provide effective relief without the side effects associated with medication.
STAT
MARCH 11, 2024
Despite being the largest minority in the nation , disabled people like us have been structurally and institutionally obstructed from entering research-dominated fields. When they do manage to break through, they are seldom given the support and accommodations needed to sustain employment and thrive in their professional lives. As we have experienced, including people with disabilities in academic leadership and decision-making positions can lead to innovation, creative problem-solving, and insi
Fierce Healthcare
MARCH 15, 2024
ORLANDO, Florida — Software giant Oracle continues to build out generative AI tools in its healthcare solutions as it debuted a new service for care management this week and plans to roll out | Oracle is integrating generative AI and ambient listening technologies into its EHR to streamline medical notetaking for clinicians. "We're not trying to go from 10 clicks to seven clicks.
Fierce Pharma
MARCH 11, 2024
The decades-long wait for an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) has ended, as the FDA has approved the first drug for the fatty liver disease. | The decades-long wait for an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) has ended. The FDA has approved Madrigal's resmetirom under the brand name Rezdiffra as the first drug for the fatty liver disease.
Drug Topics
MARCH 12, 2024
The implementation of targeted educational interventions might improve knowledge gaps, which pose great risk to patients, in type 2 diabetes (T2D) management.
Expert insights. Personalized for you.
530 
Let's personalize your content